Pharma deviation management and CAPA AI
AI for pharmaceutical deviation investigations and CAPA review
Help quality teams spend less effort finding records and more time evaluating what happened. NeoBram builds AI-assisted deviation investigation workflows around approved evidence, accountable investigators and your existing quality management process.
Assemble the evidence behind a deviation
An investigation may depend on batch records, laboratory results, equipment history, SOPs and earlier deviations held in different systems. We scope a permitted collection and build retrieval that returns the relevant passages with document identity, version and location. Missing records remain visible gaps rather than being filled with generated explanations.
A reviewer can inspect a proposed chronology of events, check dates against the originals and separate observations from assumptions. The initial project defines which record types are available, who may access them and how corrections are captured.
Prepare an illustrative investigation pack
Consider a recurring documentation deviation within one approved category. The assistant can assemble the current event, relevant controlled procedures and permitted prior cases. It can organize what was observed, what is missing and where similar wording appears. The investigator checks whether those records are genuinely relevant before using them.
A useful pack saves repeated searching while preserving the distinction between facts and hypotheses. Similar language in two investigations does not show that the causes match, and a previous CAPA is not automatically appropriate to the new event.
- Chronology: dated observations with source locations and unresolved gaps.
- Comparable cases: why each record was retrieved and differences needing review.
- Evidence questions: records or specialist input still required by the investigator.
- Draft support: structured notes or proposed wording clearly marked for qualified review.
Find similar cases without assuming the same cause
Similar-deviation search can surface earlier events by product, equipment, process step or an approved classification. Investigators need to see why a case was retrieved, whether its context differs and what evidence contradicts a proposed explanation. Recurring-deviation trends can help prioritise questions; similarity alone does not establish root cause.
For example, a repeated temperature excursion might share wording with an earlier case while involving a different sensor, operating mode or maintenance event. This is an illustrative workflow, not a claim about a measured customer result.
Support CAPA drafting and effectiveness review
A controlled assistant can organise the evidence for a corrective and preventive action draft, highlight unsupported statements and retrieve the follow-up records a reviewer requests. Your team defines the approved taxonomy, investigation method, responsibilities and effectiveness criteria.
Root-cause conclusions, action selection, due-date commitments and CAPA closure remain with authorised personnel. Model-generated suggestions require technical review, including checks that an action addresses the supported cause rather than repeating a generic recommendation.
Fit the assistant around your quality workflow
We assess document exports, repositories and available QMS interfaces before promising an integration. The scope distinguishes read-only evidence access from any approved record-writing step. Role permissions, source status, interaction logs and controlled changes are designed around the intended use.
Private or on-premises deployment can be assessed against your infrastructure, model licences and support requirements. Deployment location does not establish compliance or replace the validation activities your quality system requires.
Measure evidence quality and reviewer effort
Start with a defined investigation category and representative historical cases, including incomplete and conflicting records. Test source correctness, retrieval relevance, unsupported statements, access boundaries and reviewer correction effort. Compare total investigation effort with the current workflow; faster searching alone does not prove fewer deviations or rejected batches.
NeoBram publishes an anonymised pharmaceutical evidence-assistant case. Its reported outcomes have non-public denominators and underlying records, and cannot isolate the effect of AI from other changes. Use it to understand the workflow, not to forecast your result.
Evaluate the evidence pack with your quality team
An agreed pilot can deliver the permitted-source map, a reviewable retrieval workflow, representative historical test cases and a report of incorrect, missing or unsupported statements. Include closed cases for which qualified reviewers understand the evidence, while separating development examples from the evaluation.
Compare complete investigation-support effort, including source checking, correcting summaries and handling irrelevant matches. Track whether important evidence was missed; speed alone is not acceptance. Define how access, withdrawn records and revised procedures are handled before use. Quality owners determine the intended use and required validation, while authorized investigators retain conclusions and closure decisions.
- Define intended use: the assistance task, permitted records and decisions reserved for authorized quality staff.
- Review source controls: identities, revisions, access, withdrawn records and correction handling.
- Record evaluation findings: missing evidence, unsupported statements, reviewer corrections and limits of the tested cases.
Scope one investigation workflow
Bring a recurring deviation category, the available source systems and the person responsible for review. We can define a bounded pilot, acceptance checks and the engineering evidence your team needs.
More clarity
Questions and answers
Can AI determine the root cause of a pharma deviation?
It can retrieve evidence and propose questions or hypotheses for investigation. Qualified investigators must test those hypotheses and approve the conclusion; fluent output is not proof of causality.
Does this replace our QMS or CAPA software?
The starting scope supports your existing quality workflow. Interfaces, approved writes and responsibilities are assessed separately; a complete QMS replacement is not implied.
Can the assistant approve or close a deviation or CAPA?
No. Approval and closure remain with authorised people following your controlled procedures.
How is this different from AI batch record review?
Batch record review checks completeness, transcription and defined exceptions before QA release review. Deviation support assembles evidence for an investigation and subsequent corrective-action review.
Is the system automatically GMP validated?
No. Your responsible quality and validation teams determine intended use, risk and required evidence. NeoBram agrees its technical testing, documentation and change-control support within that scope.
What is a sensible first investigation scope?
Choose a defined deviation category with permitted records, experienced reviewers and a repeatable evidence-gathering task. That creates a more meaningful test than asking the system to investigate every type of deviation.
What information should be visible in a draft investigation summary?
Source locations, record versions where available, observed facts, unresolved gaps and any proposed interpretation requiring review. A fluent summary without traceable evidence is not a sufficient output.
Start with one business problem